The Tolmar partnership validates the Alpha DaRT platform and provides non-dilutive capital, but the 60% net sales split on supply means Alpha Tau retains only 40% of U.S. prostate cancer revenue. The key binary catalyst is ReSTART top-line data (late 2026/early 2027), a positive readout could unlock PMA submission and a potential U.S. launch. Monitor REGAIN enrollment completion and any early efficacy signals in the IMPACT pancreatic trial. The $42.2M warrant remeasurement is non-cash and should be ignored for valuation purposes.
Drug in focus
DRTS drug pipeline →Alpha DaRT
▲ Bullish Named in this 6-K- Impact
- Phase
- Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
- Time to market
- The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
- Next catalyst
- None dated
What to watchThe REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $14.27entry
- T+1 · 3mo ago −2.80%α −3.05% · $13.87
- T+5 · 3mo ago −0.07%α +0.33% · $14.26
- T+20 · 2mo ago 0.00%α +1.06% · $14.27
- T+60 · 13d ago −1.68%α −1.20% · $14.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau Medical reported H1 2026 financial results showing a net loss of $68.8M ($0.76/share), widened from $18.8M ($0.25/share) in H1 2025, driven by a $42.2M non-cash remeasurement of warrant liabilities as the stock price rose above the $11.50 strike. Operating loss increased 42.9% to $27.1M on higher R&D spend ($20.9M vs $14.2M). The company ended Q2 with $104.8M in cash/short-term deposits, up from $76.9M at year-end 2025, boosted by a $20M equity investment from Tolmar at a 25% premium and $15M upfront payment under the Tolmar collaboration for U.S. prostate cancer commercialization. Key clinical catalysts include completed enrollment in the pivotal ReSTART trial (top-line data late 2026/early 2027), promising REGAIN glioblastoma interim data, and a 100% objective response rate in a head & neck combo study with pembrolizumab. The Tolmar deal provides up to $161.5M in milestones plus 60% of net sales on supply, validating the platform but also capping U.S. prostate cancer upside for Alpha Tau.
Key Facts
- Net loss widened to $68.8M in H1 2026 from $18.8M in H1 2025, largely due to $42.2M non-cash warrant remeasurement.
- Cash, cash equivalents, short-term deposits and restricted deposits totaled $104.8M as of June 30, 2026, up from $76.9M at Dec 31, 2025.
- Tolmar collaboration: $20M equity investment at $11.99/share (25% premium to 30-day VWAP) + $15M for manufacturing capacity + up to $161.5M in milestones + 60% of net sales on supply.
- Completed enrollment in U.S. pivotal ReSTART trial (88 patients) for recurrent cSCC; top-line data expected late 2026 or early 2027.
- REGAIN glioblastoma trial: 100% local disease control, 67% complete response rate in first 3 patients; FDA cleared full enrollment.
- Head & neck combo study with pembrolizumab: 100% objective response rate (4 CR, 5 PR) and 18.2-month median OS vs 12.3-month historical benchmark.
- R&D expenses rose 47.2% to $20.9M, driven by increased clinical trial activity, raw materials, and employee costs.
- Operating loss increased 42.9% to $27.1M; total operating expenses were $27.1M vs $19.0M in H1 2025.
- Accumulated deficit reached $258.9M as of June 30, 2026.
- Company believes existing capital resources adequate to fund operations for at least two years.
Financial Impact
Net loss of $68.8M in H1 2026, driven by $42.2M non-cash warrant remeasurement. Cash position strengthened to $104.8M. Tolmar deal provides $35M upfront ($20M equity + $15M manufacturing) plus up to $161.5M in milestones and 60% of net sales on supply.
Risk Factors
- ReSTART trial top-line data may miss efficacy or safety thresholds, delaying or preventing PMA submission.
- Tolmar collaboration caps U.S. prostate cancer upside at 60% of net sales; Alpha Tau retains no direct commercialization economics for this indication.
- Clinical-stage company with no product revenue; continued reliance on equity/debt financing or partnership milestones to fund operations beyond current 2-year runway.
- Warrant liability ($47.5M) creates balance sheet volatility; further stock price appreciation would increase non-cash losses.
- Competition from established radiation therapies and emerging modalities (e.g., targeted alpha therapy, proton therapy) may limit commercial adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-087224 |
| Document: ea030079101ex99-2.htm | 0001213900-26-087224 |
| Document: ea0300791-6k_alpha.htm | 0001213900-26-087224 |
| Document: ea030079101ex99-3.htm | 0001213900-26-087224 |
| Document: 0001213900-26-087224-index-headers.html | 0001213900-26-087224 |
| Document: 0001213900-26-087224-index.html | 0001213900-26-087224 |
| Document: 0001213900-26-087224.txt | 0001213900-26-087224 |
Track record
25 reports on DRTS
9 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 12 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers